Nurse Practitioner Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Nicola Forcha

Nurse Practitioner, Gerontology Winchester, VA Nurse Practitioner

NPI 1992477814 CMS profile 11271075

607 E Jubal Early Dr, Winchester, VA 22601

Open in the dashboard

General payments

$1,377

56 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nicola Forcha of Winchester, VA is reported in the CMS Open Payments database as having received $1,377 across 56 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $15 1
2024 General $780 34
2023 General $583 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nicola Forcha
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Nicola Forcha were reported at $15. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Nicola Forcha Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $133 $44–$396 $132
2022 $0 $142 $48–$452 $149
2023 $583 $158 $53–$482 $160
2024 $780 $171 $55–$533 $164
2025 $15 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. AstraZeneca Pharmaceuticals LP $318 11 payments
  2. Novo Nordisk Inc $221 12 payments
  3. GlaxoSmithKline, LLC. $193 2 payments
  4. Amgen Inc. $166 8 payments
  5. Lilly USA, LLC $142 7 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $77 3 payments
  7. Janssen Pharmaceuticals, Inc $64 3 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $60 3 payments
  9. Pfizer Inc. $55 3 payments
  10. AbbVie, Inc. $28 1 payment
  11. Other $52 3 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $1,377 56 payments
Products named General payments · program years 2023–2025
  1. AREXVY $193 2 payments
  2. AIRSUPRA $180 4 payments
  3. RYBELSUS $173 9 payments
  4. Ozempic $173 9 payments
  5. Otezla $120 6 payments
  6. Repatha $120 6 payments
  7. MOUNJARO $116 6 payments
  8. BREZTRI $96 5 payments
  9. TRADJENTA $77 3 payments
  10. XARELTO $64 3 payments
  11. Other $517 27 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

533

Median for Nurse Practitioner: 389

Drug cost

$5,619

Median for Nurse Practitioner: $21,885

Branded share of claims

6.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rosuvastatin Calcium Generic 50 $1,356
Duloxetine Hcl Generic 19 $1,139
Atorvastatin Calcium Generic 46 $419
Gabapentin Generic 36 $403
Amlodipine Besylate Generic 70 $298
Levothyroxine Sodium Generic 29 $221
Escitalopram Oxalate Generic 27 $205
Omeprazole Generic 18 $193
Nystatin Generic 12 $137
Oxybutynin Chloride Er Oxybutynin Chloride Brand 11 $128

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$35,355

Medicare's payments for the services billed

Medicare patients

305

Average age 77

Services billed

671

187 women, 118 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Chronic kidney disease 36%
Diabetes 32%
Depression 26%
Ischemic heart disease 25%
Osteoporosis 24%
Atrial fibrillation 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $171
$171 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $59
$59 — —
RYBELSUS
  • Novo Nordisk Inc $55
$55 — —
Ozempic
  • Novo Nordisk Inc $55
$55 — —
Otezla
  • Amgen Inc. $52
$52 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

56 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record